Piramal Pharma to acquire 41% stake in Yapan Bio, making it a subsidiary

Piramal Pharma Ltd has announced the exercise of its call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company. This proposed transaction will increase Piramal Pharma's shareholding in Yapan from 33.33% to approximately 74%, thereby making Yapan a subsidiary. Yapan Bio specializes in process development and GMP manufacturing for vaccines and biologics. The final terms, including acquisition consideration and effective date, are yet to be finalized, and further disclosures will be made upon completion of definitive documentation.